Price
$0.3936
Increased by 0.00%
Dollar Volume
430.65 K
ADR%
4.58
Earnings Report Date (estimate)
Feb 13, 23 (-0.28)
Market Cap.
26.62 M
Shares Float
60.63 M
Shares Outstanding
67.63 M
Beta
1.58
Price / Earnings
-0.27
BPR
7.42
20D Range
0.36 0.43
50D Range
0.23 0.43
200D Range
0.23 2.47
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 21, 22 -0.28
Increased by +37.78%
-0.28
Sep 27, 22 -0.36
Increased by +10.00%
-0.34
Decreased by -5.88%
Sep 23, 22 -0.36
Decreased by -28.57%
-0.34
Decreased by -5.88%
May 16, 22 -0.33
Increased by +17.50%
-0.43
Increased by +23.26%
Feb 14, 22 -0.45
Increased by +25.00%
-0.38
Decreased by -18.42%
Nov 9, 21 -0.40
Increased by +33.33%
-0.35
Decreased by -14.29%
Sep 23, 21 -0.28
Increased by +50.00%
-0.40
Increased by +30.00%
May 17, 21 -0.40
Increased by +20.00%
-0.41
Increased by +2.44%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Jun 30, 22 325.00 K
Decreased by -35.00%
-18.39 M
Decreased by -51.50%
Decreased by -5.66 K%
Decreased by -133.08%
Mar 31, 22 0.00
Decreased by N/A%
-14.29 M
Increased by +3.75%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0.00
Decreased by N/A%
-19.14 M
Decreased by -23.81%
Decreased by N/A%
Decreased by N/A%
Sep 30, 21 0.00
Decreased by N/A%
-17.12 M
Decreased by -11.31%
Decreased by N/A%
Decreased by N/A%
Jun 30, 21 500.00 K
Increased by +N/A%
-12.14 M
Increased by +16.32%
Decreased by -2.43 K%
Decreased by N/A%
Mar 31, 21 0.00
Decreased by N/A%
-14.85 M
Decreased by -32.73%
Decreased by N/A%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by -100.00%
-15.46 M
Decreased by -79.31%
Decreased by N/A%
Decreased by N/A%
Sep 30, 20 0.00
Decreased by N/A%
-15.38 M
Decreased by -32.85%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.